U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Read also:

• Club World Cup crowds have wildly fluctuated, from swathes of empty seats to 'hostile' atmospheres - AP News
• What Your Sweat Could Reveal About Your Health - CNN
• Some men love anal sex more than vaginal sex. Why?
• 'In our spacesuit collection for movies, we have replicas of pretty much every historic spacesuit that's been into space.' How the son of an aerospace machinist built some of Hollywood's most iconic astronaut looks (exclusive) - Space
• Judge extends order suspending Trump’s block on Harvard’s incoming foreign students - CNN
• Gemini is getting ready to replace Google Assistant on Android - The Verge
• Jim Cramer: Why Wall Street is actually going higher after the U.S. bombed Iran - CNBC
• Consumer sentiment swings sharply higher in June as tariff anxiety recedes - Axios
• What are the most important skills a fine artist should develop in today's art world?
• How do the Sola Scrptura folks react to the Dead Sea Scrolls and other more recent discoveries of ancient Biblical texts not among those canonized by Martin Luther?